Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Oct 2018 Planned End Date changed from 30 Nov 2018 to 2 Jun 2020.
- 23 Oct 2018 Planned primary completion date changed from 30 Nov 2018 to 2 Jun 2020.